Navigation Links
Pharmacyclics Reports Third Quarter 2013 Results
Date:11/7/2013

million for the nine months ended September 30, 2013, compared to $63.4 million for the nine months ended September 30, 2012. During the nine months ended September 30, 2013, the Company recognized $65.9 million of Excess Amounts as a reduction to operating expenses. There were no Excess Amounts recognized for the nine months ended September 30, 2012. Of the Excess Amounts recognized for the nine months ended September 30, 2013, $51.5 million was recorded as a reduction to research and development expenses and $14.4 million was recorded as a reduction to general and administrative expenses.

Under the Agreement, Janssen will fund maximum Excess Amounts of $200 million and $25 million of interest thereon. To date, the Company has recorded Excess Amounts amounting to $84.0 million. The Company recognizes Excess Amounts as a reduction to operating expenses as the Company's repayment of Excess Amounts to Janssen is contingent and would become payable only after the third profitable calendar quarter for the product. Further, Excess Amounts shall be reimbursable only from the Company's share of pre-tax profits (if any) after the third profitable calendar quarter for the product.  

As of September 30, 2013, the Company had cash, cash equivalents and marketable securities of $560.1 million, compared with $317.1 million as of December 31, 2012.

As of September 30, 2013, cash, cash equivalents, marketable securities and accounts receivable from Janssen totaled approximately $612.3 million. The Company now expects to end calendar year 2013 in excess of $600 million in cash, cash equivalents, marketable securities and receivables due from Janssen.

With the progress and achievements to date, the Company expects to be profitable on a GAAP basis for the quarter and year ending December 31, 2013.

"Team Pharmacyclics has consistently improved enrollment and data submission timelines for our CLL and MCL studies over the past years. Often the
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
2. Pharmacyclics Reports Second Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
4. Pharmacyclics Reports First Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
6. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Pharmacyclics, Inc. Prices Public Offering of Common Stock
9. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
10. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
11. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015 ... ) has announced the addition of the ... Type (Ankle Replacement, Digit Replacement, Elbow Replacement, ... Forecast to 2019" report to their ... for knee replacement was valued at $4,470.9 ...
(Date:5/21/2015)... ATLANTA , May 21, 2015  CryoLife, Inc. ... tissue processing company focused on cardiac and vascular surgery, ... a quarterly cash dividend for the second quarter 2015 ... quarterly cash dividend of $0.03 per share will be ... of record as of June 12, 2015.  The ex-dividend ...
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ ... von Arzneimittelfälschungen - Zwecks Leistungsvergleich zur ... wird auf EG-Mitgliedstaaten verwiesen, in denen ... werden.  Wählen Sie ein Aegate-Land: beispielsweise ... Richtlinie zur Bekämpfung von Arzneimittelfälschungen (FMD) ...
Breaking Medicine Technology:North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3
... VisionCare Ophthalmic Technologies, Inc., a developer of ... macular degeneration (AMD), today announced upcoming scientific and ... investigational telescope implant is the first medical device ... FDA Ophthalmic Devices Advisory Panel for End-Stage AMD, ...
... 20 Pulmo BioTech Inc. (OTC Bulletin Board: PLMO; ... into a non-binding letter of intent with BioTechnology Consulting ... Product Candidate PulmoBind(TM) for development work, clinical trials and ... very pleased to have signed a non-binding LOI with ...
Cached Medicine Technology:VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of Ophthalmology and Ophthalmology Innovation Summit Meetings 2VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of Ophthalmology and Ophthalmology Innovation Summit Meetings 3Pulmo BioTech Inc. Announces Letter of Intent Regarding Proposed License of its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) 2Pulmo BioTech Inc. Announces Letter of Intent Regarding Proposed License of its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) 3Pulmo BioTech Inc. Announces Letter of Intent Regarding Proposed License of its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) 4
(Date:5/24/2015)... 24, 2015 EnviroLeather™ by LDI, ... Plus” – a classic, rugged leather grain with ... difficult stains, including ink, to be easily removed. ... suitable for corporate, healthcare, hospitality and education environments. ... EnviroLeather’s goal of developing products that are more ...
(Date:5/24/2015)... Arizona (PRWEB) May 24, 2015 ... former Millennial Media strategy executive Jay Krihak as ... Medicx looks to ramp up its expertise and ... of the Pharmaceutical and Health sectors. , Krihak ... tech executive. Most recently, Krihak led sales planning ...
(Date:5/23/2015)... Washington, D.C. (PRWEB) May 23, 2015 ... demonstration of powers of a youngster's yogic power learned ... by Sri Nithyananda Swami in Bangalore, India. , Yogamaatha, ... of more than 50 high profile professionals attending the ... D.C. by reading fluently -- blindfolded. , In ...
(Date:5/23/2015)... On May 16, the team at ... a 5k mud obstacle run that raised funds for multiple ... worldwide, and the reason we participated was to support people ... of Farrell’s eXtreme Bodyshaping. “One-hundred percent of the funds raised ... event was not only attended by eXtreme Bodyshaping staff, but ...
(Date:5/23/2015)... CA (PRWEB) May 23, 2015 Add High-Quality ... from Pixel Film Studios. , It's as simple as dragging ... utilizing the included tool for full effect. , Including ... on high-dynamic range 5k sensors making this the ultimate bundle ... prismatic flares included in this package are movie files designed ...
Breaking Medicine News(10 mins):Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2
... Over ... their subscribers and readers demand for more alkaline and organic food…, , ... (PRWEB) June 14, 2010 -- TheAlkalineDiet.org has just ... products from all over the world. Since the launch of the website in November 2009, ...
... patients who directly confronted the stress of the Second Lebanon ... with the situation by focusing on feelings. This has been ... the University of Haifa, the Technion-Israel Institute of Technology and ... sclerosis to date, it is important to uncover all the ...
... recommended A1c blood test cutoff didn,t accurately diagnose elderly ... -- Despite its endorsement last year by the American ... 2 diabetes, new research out of Singapore suggests that ... the disease among elderly Asians. , The American Diabetes ...
... ... Horizon Healthcare Services, Inc. to Put Evidence-Based Medicine into Practice with Via Oncology Pathways ... Pittsburgh ... will continue to improve as a result of wider application of Via Oncology™ Pathways, ...
... ... ,Camera to data toggle application revolutionizes any Windows Mobile Device with Camera and replaces any ... ... of the Kodak roll film camera in 1888, engineers, inspectors and professionals have used a ...
... ... The Verdin Company announced today it has acquired ... a leader in manufacturing architectural site furnishings. The Verdin Company, ... installer of clocks, bells, carillons, bell and clock towers, glockenspiels, and ...
Cached Medicine News:Health News:Official Alkaline Diet Site Launches Organic Food Store for Healthy Living And Natural Weight Loss 2Health News:Official Alkaline Diet Site Launches Organic Food Store for Healthy Living And Natural Weight Loss 3Health News:Can multiple sclerosis attacks be minimized in a war zone? 2Health News:Age, Race May Affect Type 2 Diabetes Screening Results 2Health News:Hematology-Oncology Associates of Northern New Jersey (HOANNJ) Joins Effort to Improve Cancer Care with Via Oncology™ Pathways 2Health News:Hematology-Oncology Associates of Northern New Jersey (HOANNJ) Joins Effort to Improve Cancer Care with Via Oncology™ Pathways 3Health News:Mobile and Patented: DATA-TO-CAMERA TOGGLE on handheld device replaces old camera and clipboard approach everywhere! Beats IPAD to camera punch too..... 2Health News:The Verdin Company Acquires Canterbury International, an industry leader in architectural site furnishings for over 50 years 2Health News:The Verdin Company Acquires Canterbury International, an industry leader in architectural site furnishings for over 50 years 3
Beckman-Weitlaner retractor, blunt, with hinged arms, 6 1/2"....
Weitlaner retractor, blunt....
Halle bone curette, 8 1/4, oval, malleable shaft, 4 mm wide....
Bruns (Volkmann) bone curette, with Novotex plastic handle (autoclavable in autoclave up to 143C by 3 bar), 9, oval....
Medicine Products: